Evidence map›Paper›PMID 40495382›Full record

Observational studyHGG advances2025

The impact of genetic ancestry on survival outcomes in pediatric rhabdomyosarcoma: A report from the Children's Oncology Group.

Ekene A Onwuka, Christina L Magyar, Bailey A Martin-Giacalone, Michael E Scheurer, Deborah A Marquez-Do, Mark Zobeck, Elizabeth G Atkinson, Erin R Rudzinski, Michael A Arnold, Donald A Barkauskas and 12 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in HGG advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Ekene A OnwukaDepartment of Pediatric Surgery, Surgical Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX 77030, USA.
Christina L MagyarGraduate Program in Genetics and Genomics, Baylor College of Medicine, Houston, TX 77030, USA; Medical Scientist Training Program, Baylor College of Medicine, Houston, TX 77030, USA; McNair Medical Institute, The Robert and Janice McNair Foundation, Houston, TX 77030, USA; Department of Pediatrics, Section of Hematology-Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX 77030, USA.
Bailey A Martin-GiacaloneDepartment of Pediatrics, Section of Hematology-Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX 77030, USA.
Michael E ScheurerDepartment of Pediatrics, Section of Hematology-Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX 77030, USA; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Pediatrics, Emory University School of Medicine, Atlanta University, Atlanta, GA, USA; Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta, Atlanta, GA, USA.
Deborah A Marquez-DoDepartment of Pediatrics, Section of Hematology-Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX 77030, USA.
Mark ZobeckDepartment of Pediatrics, Section of Hematology-Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX 77030, USA.
Elizabeth G AtkinsonDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX 77030, USA.
Erin R RudzinskiDivision of Hematology-Oncology, Seattle Children's Hospital, University of Washington, Seattle, WA 98105, USA.
Michael A ArnoldDepartment of Pathology and Laboratory Medicine, Children's Hospital Colorado, Aurora, CO 80045, USA; Department of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.
Donald A BarkauskasDepartment of Population and Public Health Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90032, USA; QuadW Childhood Sarcoma Biostatistics and Annotation Office, Children's Oncology Group, Monrovia, CA 91016, USA.
David HallQuadW Childhood Sarcoma Biostatistics and Annotation Office, Children's Oncology Group, Monrovia, CA 91016, USA.
Javed KhanOncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Jack F ShernPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Paul ScheetDepartment of Epidemiology at the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Brian CromptonDana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA 02141, USA.
Corinne M LinardicDepartments of Pediatrics and Pharmacology & Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.
Douglas S HawkinsDivision of Hematology-Oncology, Seattle Children's Hospital, University of Washington, Seattle, WA 98105, USA.
Rajkumar VenkatramaniDepartment of Pediatrics, Section of Hematology-Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX 77030, USA.
Lisa MirabelloClinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD 20892, USA.
Chad D HuffDepartment of Epidemiology at the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Melissa A RichardDepartment of Pediatrics, Section of Hematology-Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX 77030, USA; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Philip J LupoDepartment of Pediatrics, Section of Hematology-Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX 77030, USA; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Pediatrics, Emory University School of Medicine, Atlanta University, Atlanta, GA, USA; Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta, Atlanta, GA, USA. Electronic address: plupo@emory.edu.

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Empowering gene discovery and accelerating clinical translation for diverse admixed populationsR01HG012869 · NHGRI · BAYLOR COLLEGE OF MEDICINE · PI Elizabeth Grace Atkinson · 2023 to 2026
$3.1M
NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NHGRI NIH HHS R01 HG012869
6 · The paper itself

Abstract

Emerging evidence suggests genetic ancestry may influence childhood cancer outcomes, but its impact on pediatric rhabdomyosarcoma (RMS) is unknown. We explored genetic ancestry's impact on survival among children with RMS. This multi-center observational cohort study is a secondary analysis of previously collected biobanking, genomic, and clinical data. The study included 920 individuals with newly diagnosed RMS under 40 years of age enrolled from 2005 to 2017 under the COG soft tissue sarcoma biobanking protocol D9902. The primary endpoints were (1) event-free survival (EFS), defined as the time from study enrollment to tumor recurrence/progression, secondary malignancy, or death from any cause; and (2) overall survival (OS), defined as the time from study enrollment to death from any cause. Genetic ancestry was estimated using Grafpop software, and Cox regression assessed the association between genetic ancestry and EFS and OS, considering RMS overall, by fusion status, and by histological subtype. Covariates included sex, age at diagnosis, tumor stage, and histology, except during stratified analyses. In embryonal RMS and PAX3/7:FOXO1 fusion-negative RMS, individuals with South Asian or Asian-Pacific Islander ancestry showed worse EFS (hazard ratio [HR] 2.06, 95% confidence interval [CI] 1.07-3.97, p = 0.03 and HR 2.01, 95% CI 1.07-3.76, p = 0.03, respectively) and OS (HR 2.30, 95% CI 1.09-4.84, p = 0.03 and HR 2.33, 95% CI 1.15-4.70, p = 0.020, respectively) compared to those with primarily European genetic ancestry. These findings suggest that genetic ancestry influences survival outcomes within RMS subtypes, and further understanding may improve precision-medicine-based efforts.

Indexed as

RhabdomyosarcomaAdolescentChildChild, PreschoolFemaleHumansInfantMalePrognosisYoung Adultgenetic ancestryhealth disparitiesrhabdomyosarcomaSouth Asian/Asian-Pacific Islandersurvival outcomes

Identifiers

PMID40495382
PMCPMC12256324

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.